Ask AI
ProCE Banner Activity

Oncology Pharmacy Think Tank: Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Slideset

Download these slides from a recent webinar to gain a deeper understanding on how to optimize care for your patients with HR-positive/HER2-negative breast cancer by enhancing your understanding of CDK4/6 inhibitors and their associated toxicities.

Released: February 10, 2026

Continue Activity

Share

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Lilly.

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for oncology pharmacists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Effectively mitigate and manage toxicities associated with CDK4/6 inhibitor therapy for patients with HR+/HER2- breast cancer, including recommended dose modification strategies

  • Implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in patients with HR+/HER2- breast cancer

  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy in patients with HR+/HER2- breast cancer